Cheshire, UK--(Marketwire - March 6, 2008) -
Protherics PLC
Application for Block listing
London, UK; Brentwood, TN, US: 6 March 2008 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, announces that today, application has been made to the UK
Listing Authority and the London Stock Exchange for the block listing of 259,014
ordinary shares of 2p each in the Company (the "Shares") to be admitted to
trading on the Official List and to trading on London Stock Exchange's main
market. The Shares will be used to fulfil the Company's requirement to allot
shares pursuant to the exercise of options under the terms of the Company's 2005
Long-Term Incentive Plan and 2005 Deferred Bonus Plan.
The Shares will rank equally with the existing issued ordinary shares of the
Company and are expected to commence trading around 7 March 2008.
Following admission of the Shares, the Company's issued share capital will be
340,187,189 Ordinary Shares.
| Ends |
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange